5
Perk Pharmaceuticals
530673 BSE
Perk Pharmaceuticals
Healthcare BSE: 530673 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
2- Company has reduced debt.
- Company is almost debt free.
Weaknesses
4- The company has delivered a poor sales growth of 1.20% over past five years.
- Company has a low return on equity of 2.58% over last 3 years.
- Company has high debtors of 588 days.
- Company's cost of borrowing seems high
Growth Rate
Revenue Growth
-8% lower than
3Y
Net Income Growth
-79% lower than
3Y
Quarterly Results
| Particulars | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 7.44 | 8.25 | 5.17 | 6.68 | 11.87 | 13.82 | 14.87 |
| Expenses | 7.38 | 8.3 | 12.24 | 6.65 | 11.64 | 13.75 | 14.32 |
| Operating Profit | 0.06 | -0.05 | -7.07 | 0.03 | 0.23 | 0.07 | 0.55 |
| OPM % | 0.81% | -0.61% | -136.75% | 0.45% | 1.94% | 0.51% | 3.7% |
| Other Income | 0.33 | 0.83 | -0.77 | 0.39 | 0.36 | 1.64 | 0.2 |
| Interest | 0.02 | 0.12 | 0.06 | 0.34 | 0.18 | 0.03 | 0.03 |
| Depreciation | 0.02 | 0.05 | -0.05 | 0.02 | 0.08 | 0.14 | 0.16 |
| PBT | 0.35 | 0.61 | -7.85 | 0.06 | 0.33 | 1.54 | 0.56 |
| Tax % | 17.14% | 21.31% | -1.15% | -1116.67% | 33.33% | 13.64% | 14.29% |
| Net Profit | 0.29 | 0.49 | -7.76 | 0.73 | 0.22 | 1.33 | 0.47 |
| EPS in Rs | 0.69 | 0.33 | -5.24 | 0.49 | 0.14 | 0.86 | 0.3 |
Profit & Loss
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
|---|---|---|---|---|---|---|
| Sales | 1.14 | 1.42 | 1.3 | 1.4 | 1.32 | 1.21 |
| Expenses | 1.64 | 1.14 | 1.43 | 1.2 | 0.81 | 0.97 |
| Operating Profit | -0.5 | 0.28 | -0.13 | 0.2 | 0.51 | 0.24 |
| OPM % | -43.86% | 19.72% | -10% | 14.29% | 38.64% | 19.83% |
| Other Income | 0 | 0 | 0.01 | 0 | 0 | 0 |
| Interest | 0.04 | 0.05 | 0.02 | 0.03 | 0.04 | 0.03 |
| Depreciation | 0.14 | 0.13 | 0.16 | 0.15 | 0.14 | 0.14 |
| PBT | -0.68 | 0.1 | -0.3 | 0.02 | 0.33 | 0.07 |
| Tax % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | -0.68 | 0.1 | -0.3 | 0.02 | 0.33 | 0.07 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
|---|---|---|---|---|---|---|
| Equity Capital | 6.38 | 6.38 | 6.38 | 6.38 | 6.38 | 6.38 |
| Reserves | -2.61 | -0.85 | -1.15 | -1.13 | -0.79 | -0.72 |
| Borrowings | 0.47 | 0.35 | 0.46 | 0.33 | 0.27 | 0.02 |
| Other Liabilities | 1.07 | 0.99 | 0.85 | 0.42 | 0.85 | 1.4 |
| Total Liabilities | 5.31 | 6.87 | 6.54 | 6 | 6.71 | 7.08 |
| Fixed Assets | 2.87 | 4.39 | 4.17 | 4.02 | 3.88 | 3.82 |
| CWIP | 0.08 | 0.08 | 0.1 | 0.1 | 0.1 | 0.1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 2.36 | 2.4 | 2.27 | 1.88 | 2.73 | 3.16 |
| Total Assets | 5.31 | 6.87 | 6.54 | 6 | 6.71 | 7.08 |
Cash Flow
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
|---|---|---|---|---|---|---|
| Operating | 0.02 | 0.15 | 0.03 | -0.08 | 0.05 | 0.58 |
| Investing | -0.03 | -0.01 | 0.03 | 0 | 0 | -0.08 |
| Financing | 0.01 | -0.12 | 0.11 | -0.13 | -0.05 | -0.25 |
| Net Cash Flow | 0 | 0.02 | 0.17 | -0.21 | 0 | 0.25 |
| Free Cash Flow | -0.01 | 0.14 | 0.06 | -0.08 | 0.05 | 0.5 |
| CFO/OP | -4 | 54 | -23 | -40 | 10 | 242 |
Ratios
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 |
|---|---|---|---|---|---|---|
| Debtor Days | 106 | 139 | 168 | 224 | 462 | 588 |
| Inventory Days | 471 | 849 | 386 | 419 | 730 | 557 |
| Days Payable | 118 | 225 | 153 | 150 | 344 | 767 |
| Cash Conversion Cycle | 459 | 764 | 401 | 493 | 848 | 378 |
| Working Capital Days | 362 | 324 | 314 | 362 | 503 | 437 |
| ROCE % | — | 2.96% | -4.84% | 0.89% | 6.47% | 1.73% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Perk Pharmaceuticals insights
28 extracted metrics + investor summaries across FY06–FY11.
Documents
1
General Updates
10 March 2026 - Gretex incorporated Gretex Music Ecosystems Pvt Ltd on March 10, 2026; subscribed 51% (Rs.51,000). 10 March 2026 - Gretex incorporated Gretex Music Ecosystems Pvt Ltd on March 10, 2026; subscribed 51% (Rs.51,000).
2
Press Release
2 March 2026 - Gretex Industries Limited has informed regarding a press release dated March 02, 2026, titled Gretex EZ Properties LLP Commences INM Franchise Operations in Mumbai . 2 March 2026 - Gretex Industries Limited has informed regarding a press release dated March 02, 2026, titled Gretex EZ Properties LLP Commences INM Franchise Operations in Mumbai .
3
Outcome of Board Meeting
27 February 2026 - 27-Feb-2026: Board approved three subsidiaries; Gretex Aran 98%, Gretex Music Room 98%, Music Ecosystem 51%. 27 February 2026 - 27-Feb-2026: Board approved three subsidiaries; Gretex Aran 98%, Gretex Music Room 98%, Music Ecosystem 51%.
4
General Updates
17 February 2026 - Paid Rs1 Crore advance for property on behalf of proposed subsidiary Gretex Aran Properties LLP; completion within six months. 17 February 2026 - Paid Rs1 Crore advance for property on behalf of proposed subsidiary Gretex Aran Properties LLP; completion within six months.
5
General Updates
14 February 2026 - Gretex Industries Limited has informed about General Updates 14 February 2026 - Gretex Industries Limited has informed about General Updates
Frequently Asked Questions about Perk Pharmaceuticals
What does Perk Pharmaceuticals Ltd do?
Perk Pharmaceuticals Ltd. engages in manufactures and markets specialty pharmaceuticals.
Where is Perk Pharmaceuticals Ltd (530673) listed?
Perk Pharmaceuticals Ltd trades under code 530673 on the BSE.
Which sector does Perk Pharmaceuticals Ltd belong to?
Perk Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Perk Pharmaceuticals Ltd. engages in manufactures and markets specialty pharmaceuticals.
Website perkpharma.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/530673.md for Perk Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.